423 related articles for article (PubMed ID: 31973936)
21. Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial.
Sonneveld P; Chanan-Khan A; Weisel K; Nooka AK; Masszi T; Beksac M; Spicka I; Hungria V; Munder M; Mateos MV; Mark TM; Levin MD; Ahmadi T; Qin X; Garvin Mayo W; Gai X; Carey J; Carson R; Spencer A
J Clin Oncol; 2023 Mar; 41(8):1600-1609. PubMed ID: 36413710
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness analysis on binary/triple therapy on the basis of ixazomib or bortezomib for refractory or relapsed multiple myeloma.
Cai H; Zhang L; Li N; Zheng B; Liu M
Leuk Lymphoma; 2019 Dec; 60(12):2951-2959. PubMed ID: 31161831
[TBL] [Abstract][Full Text] [Related]
23. Daratumumab plus bortezomib and dexamethasone
Spencer A; Lentzsch S; Weisel K; Avet-Loiseau H; Mark TM; Spicka I; Masszi T; Lauri B; Levin MD; Bosi A; Hungria V; Cavo M; Lee JJ; Nooka AK; Quach H; Lee C; Barreto W; Corradini P; Min CK; Scott EC; Chanan-Khan AA; Horvath N; Capra M; Beksac M; Ovilla R; Jo JC; Shin HJ; Sonneveld P; Soong D; Casneuf T; Chiu C; Amin H; Qi M; Thiyagarajah P; Sasser AK; Schecter JM; Mateos MV
Haematologica; 2018 Dec; 103(12):2079-2087. PubMed ID: 30237264
[TBL] [Abstract][Full Text] [Related]
24. Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients With Relapsed or Refractory Multiple Myeloma: Updated Analysis of LEPUS.
Fu W; Li W; Hu J; An G; Wang Y; Fu C; Chen L; Jin J; Cen X; Ge Z; Cai Z; Niu T; Qi M; Gai X; Li Q; Liu W; Liu W; Yang X; Chen X; Lu J
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e51-e58. PubMed ID: 36402700
[TBL] [Abstract][Full Text] [Related]
25. Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma.
Patel KK; Giri S; Parker TL; Bar N; Neparidze N; Huntington SF
J Clin Oncol; 2021 Apr; 39(10):1119-1128. PubMed ID: 33411586
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States.
Carlson JJ; Guzauskas GF; Chapman RH; Synnott PG; Liu S; Russo ET; Pearson SD; Brouwer ED; Ollendorf DA
J Manag Care Spec Pharm; 2018 Jan; 24(1):29-38. PubMed ID: 29290170
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
Jakubowiak AJ; Campioni M; Benedict Á; Houisse I; Tichy E; Giannopoulou A; Aggarwal SK; Barber BL; Panjabi S
J Med Econ; 2016 Nov; 19(11):1061-1074. PubMed ID: 27224006
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
Usmani SZ; Cavenagh JD; Belch AR; Hulin C; Basu S; White D; Nooka A; Ervin-Haynes A; Yiu W; Nagarwala Y; Berger A; Pelligra CG; Guo S; Binder G; Gibson CJ; Facon T
J Med Econ; 2016; 19(3):243-58. PubMed ID: 26517601
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR.
Avet-Loiseau H; San-Miguel J; Casneuf T; Iida S; Lonial S; Usmani SZ; Spencer A; Moreau P; Plesner T; Weisel K; Ukropec J; Chiu C; Trivedi S; Amin H; Krevvata M; Ramaswami P; Qin X; Qi M; Sun S; Qi M; Kobos R; Bahlis NJ
J Clin Oncol; 2021 Apr; 39(10):1139-1149. PubMed ID: 33513030
[TBL] [Abstract][Full Text] [Related]
30. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies.
Mateos MV; Spencer A; Nooka AK; Pour L; Weisel K; Cavo M; Laubach JP; Cook G; Iida S; Benboubker L; Usmani SZ; Yoon SS; Bahlis NJ; Chiu C; Ukropec J; Schecter JM; Qin X; O'Rourke L; Dimopoulos MA
Haematologica; 2020; 105(2):468-477. PubMed ID: 31221782
[TBL] [Abstract][Full Text] [Related]
31. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).
Bahlis NJ; Baz R; Harrison SJ; Quach H; Ho SJ; Vangsted AJ; Plesner T; Moreau P; Gibbs SD; Coppola S; Yang X; Al Masud A; Ross JA; Bueno O; Kaufman JL
J Clin Oncol; 2021 Nov; 39(32):3602-3612. PubMed ID: 34388020
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States.
Kumar SK; Majer I; Panjabi S; Medhekar R; Campioni M; Dimopoulos MA
Expert Rev Hematol; 2020 Jun; 13(6):687-696. PubMed ID: 32249621
[TBL] [Abstract][Full Text] [Related]
33. Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials.
Dhakal B; Narra RK; Giri S; Szabo A; Smunt TL; Ghose S; Pathak LK; Aryal M; Hamadani M; Chhabra S; Janz S; D'Souza A; Hari PN
Cancer; 2020 Jun; 126(12):2791-2801. PubMed ID: 32154922
[TBL] [Abstract][Full Text] [Related]
34. Comparative Efficacy of Treatments for Previously Treated Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.
Maiese EM; Ainsworth C; Le Moine JG; Ahdesmäki O; Bell J; Hawe E
Clin Ther; 2018 Mar; 40(3):480-494.e23. PubMed ID: 29500140
[TBL] [Abstract][Full Text] [Related]
35. Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients-a single-center retrospective study.
Regidor B; Goldwater MS; Wang J; Bujarski S; Swift R; Eades B; Emamy-Sadr M; Eshagian S; Schwartz G; Spektor TM; Berenson JR
Ann Hematol; 2021 Aug; 100(8):2061-2070. PubMed ID: 33987683
[TBL] [Abstract][Full Text] [Related]
36. A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis.
Weisel K; Sonneveld P; Spencer A; Beksac M; Rizzo M; Xu Y; Fahrbach K; Gaudig M; Slavcev M; Dearden L; Lam A
Leuk Lymphoma; 2019 Jan; 60(1):151-162. PubMed ID: 30407092
[TBL] [Abstract][Full Text] [Related]
37. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Palumbo A; Chanan-Khan A; Weisel K; Nooka AK; Masszi T; Beksac M; Spicka I; Hungria V; Munder M; Mateos MV; Mark TM; Qi M; Schecter J; Amin H; Qin X; Deraedt W; Ahmadi T; Spencer A; Sonneveld P;
N Engl J Med; 2016 Aug; 375(8):754-66. PubMed ID: 27557302
[TBL] [Abstract][Full Text] [Related]
38. A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma.
Richard S; Jagannath S; Cho HJ; Parekh S; Madduri D; Richter J; Chari A
Expert Rev Hematol; 2021 Jan; 14(1):31-45. PubMed ID: 33331794
[No Abstract] [Full Text] [Related]
39. Real-world effectiveness and safety of daratumumab, bortezomib and dexamethasone in relapsed/refractory multiple myeloma in Slovakia.
Harvanová Ľ; Štulajterová V; Guman T; Ladická M; Hlebašková M; Chudej J; Šimek M; Štecová N; Flochová E; Kubala J; Simančíková I; Drgoňa Ľ; Vranovský A; Wild A; Mistrík M; Bátorová A
Neoplasma; 2021 May; 68(3):626-630. PubMed ID: 33567854
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma.
Wong XY; Chng WJ; Aziz MIA; Ng K
Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):207-215. PubMed ID: 34904498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
